



AHA 2025 (American Heart Association)

November 7-10, 2025; New Orleans, LA; Resource Hub – Draft

Welcome to our resource hub for AHA 2025. This is a one-stop-shop for all your AHA needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Table of Contents

[Useful Conference Links](#)

[Diabetes Therapy Highlights](#)

[Diabetes Big Picture Highlights](#)

[Day-by-Day Highlights](#)

[Previous AHA Coverage on CCKB](#)

Useful Conference Links

- [Conference Website](#)
- [Conference Registration](#)
- [Schedule at a Glance](#)

Diabetes Therapy Highlights

1. [GLP-1 RAs are associated with better all-cause mortality and CV outcomes in people with hypertrophic cardiomyopathy](#)
2. [APOC3 and HDL particle composition as drivers of CVD risk in T1D](#)
3. [RAGE/DIAPH1 as a novel therapeutic target for diabetic complications](#)
4. [Prespecified analysis of SURPASS-CVOT](#): Baseline SGLT-2 inhibitor use or initiation does not affect CV benefits of tirzepatide or dulaglutide
5. [Combination therapy with GLP-1 RAs and SGLT-2 inhibitors](#) in T2D
6. [Triple GLP-1/glucagon/FGF-21 RA demonstrates significant metabolic benefits](#) and liver fat reduction in a phase 2 trial
7. [Pre-specified SURPASS-CVOT](#): Tirzepatide reduces risk of coronary revascularization and hospitalization due to unstable angina in people with T2D when compared with dulaglutide
8. [Tirzepatide and semaglutide demonstrate cardiovascular benefits](#) in people with T2D in real-world settings
9. [Dual SGLT-1/SGLT-2 inhibitor sotagliflozin](#) shows consistent ~40% MACE reduction across pooled phase 3 T2D trials, reinforcing SCORED findings
10. [Pre-specified of FINE-HEART finds finerenone reduces sudden death](#) across cardiovascular-kidney-metabolic syndrome
11. [Cardioprotective mechanisms behind GLP-1 RAs](#) are independent of A1c reduction or weight loss
12. [Pre-specified analysis of SURPASS-CVOT finds that tirzepatide](#) is superior to dulaglutide for the composite of all-cause death and HF events
13. [GLP-1 RAs as more than a weight loss therapy](#): Dr. Rodica Busui on the SOUL trial and the new era of precision medicine

14. [Reconsidering the role of incretin therapies](#): Shifting the focus toward peripheral artery disease
15. [Heart and liver protection from GLP-1 RAs](#) are independent of weight loss
16. [Real-world and post-trial evidence across semaglutide and tirzepatide](#): Implications for cardiovascular risk
17. [SELECT post-hoc analysis](#): Semaglutide demonstrated benefits regardless of baseline frailty status
18. [Early GLP-1 RA use and benefits](#) across diverse older and high-risk populations
19. [Finerenone in the liver](#): Post-hoc analysis of FINEARTS-HF trial

Diabetes Big Picture Highlights

1. [Landmark VESALIUS-CV trial](#) supports early and intensive lipid management in people with high CV risk or atherosclerosis, including PWD
2. [The “pillars” of DKD](#): Best clinical practices for minimizing cardiovascular risk in people with DKD
3. [Dr. Richard Pratley on the mechanistic link](#) between diabetic kidney disease and CVD: Metabolic aging and environmental factors
4. [Bonus Highlight! Administrator Dr. Mehmet Oz highlights CMS’s efforts](#) to “Make America Healthy Again”
5. [Drs. Deepak L. Bhatt, Christie Ballantyne, and Erin Michos on cardiometabolic interventions](#) on atherosclerosis
6. [Cardiovascular-kidney-liver-metabolic syndrome](#): Prevention, screening, and management strategies led by risk-stratification
7. [Redefining obesity](#): Moving beyond BMI toward mechanisms, early markers, and the lived patient experience
8. [Closing the CKM care gap](#) through equitable access and interdisciplinary care models
9. [AHA 2025’s exhibit hall buzzes](#) with free ASCVD testing, puppies, VR simulations, and more!
10. [Prof. Stephen Nicholls on the SURPASS-CVOT trial as a turning point](#) for CVOT trial design
11. [Presence of diabetes significantly amplifies cardiovascular risk](#) in individuals with elevated Lp(a)

Day-by-Day Highlights

1. [AHA Day #1 Highlights](#)
2. [AHA Day #2 Highlights](#)
3. [AHA Day #3 Highlights](#)
4. [AHA Day #4 Highlights](#)

Previous AHA Coverage on CCKB

- [AHA 2024 Resource Hub](#)
- [AHA 2023 Resource Hub](#)
- [AHA 2022 Resource Hub](#)
- [AHA 2021 Resource Hub](#)
- [AHA 2020 Day #1 Highlights](#)
- [AHA 2020 Day #2-3 Highlights](#)
- [AHA 2020 Day #4 Highlights](#)
- [AHA 2020 Day #5 Highlights](#)
- [AHA 2019 Highlights Report #1](#)
- [AHA 2019 Highlights Report #2](#)

- [AHA 2018 Full Report](#)
- [AHA 2017 Full Report](#)
- [AHA 2016 Full Report](#)
- [AHA 2015 Full Report](#)